Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization

Diagnostic and Statistical Manual of Mental Disorders

Williams, J. B. W., & First, M. B. (2013) · Oxford University Press eBooks · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,845

“Mini-mental state”

Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282

Clinical diagnosis of Alzheimer's disease: Report of the NINCDS‐ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012

Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,722

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431

Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease Aβ Synaptotoxicity

Klyubin, I., Nicoll, A. J., Khalili-Shirazi, A., Farmer, M., Canning, S., Mably, A., Linehan, J., Brown, A., Wakeling, M., Brandner, S., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3526-13.2014 · Cited by 74

Synthesis and in vitro carbonic anhydrases and acetylcholinesterase inhibitory activities of novel imidazolinone‐based benzenesulfonamides

Tugrak, M., Gul, H. I., Demir, Y., Levent, S., & Gülçın, İ. (2020) · Archiv der Pharmazie · doi:10.1002/ardp.202000375 · Cited by 74

Metal compounds as inhibitors of β-amyloid aggregation. Perspectives for an innovative metallotherapeutics on Alzheimer's disease

Valensin, D., Gabbiani, C., & Luigi Messori, A. (2012) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2012.04.010 · Cited by 77

Amyloid β (Aβ) and phospho-tau (p-tau) as diagnostic biomarkers in Alzheimer's disease

Prvulovic, D., & Hampel, H. J. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.087 · Cited by 76

RNA aptamers selected against amyloid β-peptide (Aβ) inhibit the aggregation of Aβ

Takahashi, T., Tada, K., & Mihara, H. (2009) · Molecular BioSystems · doi:10.1039/b903391b · Cited by 75

The morphology and biochemistry of nanostructures provide evidence for synthesis and signaling functions in human cerebrospinal fluid

Harrington, M. G., Fonteh, A. N., Oborina, E., Liao, P. S., Cowan, R. P., McComb, J. G., Chavez, J. N., Rush, A. J., Biringer, R. G., & Hühmer, A. F. R. (2009) · Cerebrospinal Fluid Research · doi:10.1186/1743-8454-6-10 · Cited by 75

Isolation of Low-n Amyloid β-Protein Oligomers from Cultured Cells, CSF, and Brain

Shankar, G. M., Welzel, A. T., McDonald, J. M., Selkoe, D. J., & Walsh, D. M. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-744-0_3 · Cited by 72

APP transgenic mice: their use and limitations

Balducci, C., & Forloni, G. (2011) · NeuroMolecular Medicine · doi:10.1007/s12017-010-8141-7 · Cited by 79

Aβ dimers differ from monomers in structural propensity, aggregation paths and population of synaptotoxic assemblies

O’Malley, T. T., Oktaviani, N. A., Zhang, D., Lomakin, A., O’Nuallain, B., Linse, S. S., Benedek, G. B., Rowan, M. J., Mulder, F. A. A., & Walsh, D. M. (2014) · Biochemical Journal · doi:10.1042/bj20140219 · Cited by 68

Copper-mediated β-amyloid toxicity and its chelation therapy in Alzheimer's disease

Singh, S. K., Balendra, V., Obaid, A. A., Esposto, J., Tikhonova, M. A., Gautam, N. K., & Pöeggeler, B. (2022) · Metallomics · doi:10.1093/mtomcs/mfac018 · Cited by 68

Disruption of neocortical histone H3 homeostasis by soluble Aβ: implications for Alzheimer's disease

Lithner, C. U., Lacor, P. N., Zhao, W.-Q., Mustafiz, T., Klein, W. L., Sweatt, J. D., & Hernandez, C. M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.12.028 · Cited by 67

Generalization of the Prion Hypothesis to Other Neurodegenerative Diseases: An Imperfect Fit

Guest, W. C., Silverman, J. M., Pokrishevsky, E., O’Neill, M. A., Grad, L. I., & Cashman, N. R. (2011) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2011.618967 · Cited by 67

Inhibition of Alzheimer’s amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo

Hong, H., Rana, S., Barrigan, L. M., Shi, A., Zhang, Y., Zhou, F., Jin, L., & Hua, D. H. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05866.x · Cited by 68

Impairments of glutamatergic synaptic transmission in Alzheimer’s disease

Zott, B., & Konnerth, A. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.03.013 · Cited by 66

Reversal of LTP-Like Cortical Plasticity in Alzheimer’s Disease Patients with Tau-Related Faster Clinical Progression

Koch, G., Lorenzo, F. D., Fernández‐del‐Olmo, M., Bonnı̀, S., Ponzo, V., Caltagirone, C., Bozzali, M., & Martorana, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150813 · Cited by 68

Antibody-Based Drugs and Approaches Against Amyloid-β Species for Alzheimer’s Disease Immunotherapy

Liu, J., Yang, B., Ke, J., Li, W., & Suen, W.-C. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0406-x · Cited by 67

Alzheimer brain-derived amyloid β-protein impairs synaptic remodeling and memory consolidation

Borlikova, G. G., Trejo, M., Mably, A. J., Donald, J. M. M., Frigerio, C. S., Regan, C. M., Murphy, K. J., Masliah, E., & Walsh, D. M. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.028 · Cited by 65

The functional neurophysiology of the amyloid precursor protein (APP) processing pathway

Randall, A. D., Witton, J., Booth, C., Hynes-Allen, A. M., & Brown, J. T. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.02.011 · Cited by 66

The Quest for Small Molecules as Amyloid Inhibiting Therapies for Alzheimer's Disease

Amijee, H., & Scopes, D. I. C. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1044 · Cited by 65

Copper Redox Cycling Inhibits Aβ Fibre Formation and Promotes Fibre Fragmentation, while Generating a Dityrosine Aβ Dimer

Gu, M., Bode, D. C., & Viles, J. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-33935-5 · Cited by 66

Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer’s disease

Li, S., Jin, M., Liu, L., Dang, Y., Ostaszewski, B. L., & Selkoe, D. J. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0626-x · Cited by 64

Targets for AD treatment: conflicting messages from γ-secretase inhibitors

Sambamurti, K., Greig, N. H., Utsuki, T., Barnwell, E., Sharma, E., Mazell, C., Bhat, N. R., Kindy, M. S., Lahiri, D. K., & Pappolla, M. A. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07213.x · Cited by 62

β-Amyloid (1–40) Peptide Interactions with Supported Phospholipid Membranes: A Single-Molecule Study

Ding, H., Schauerte, J. A., Steel, D. G., & Gafni, A. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.08.051 · Cited by 61

The levels of water-soluble and triton-soluble Aβ are increased in Alzheimer's disease brain

McDonald, J. M., Cairns, N. J., Taylor‐Reinwald, L., Holtzman, D. M., & Walsh, D. M. (2012) · Brain Research · doi:10.1016/j.brainres.2012.02.041 · Cited by 61

LncRNA BDNF-AS as ceRNA Regulates the miR-9-5p/BACE1 Pathway Affecting Neurotoxicity in Alzheimer's disease

Ding, Y., Luan, W., Shen, X., Wang, Z., & Cao, Y. (2021) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2021.104614 · Cited by 60

Efavirenz Promotes β-Secretase Expression and Increased Aβ1-40,42 via Oxidative Stress and Reduced Microglial Phagocytosis: Implications for HIV Associated Neurocognitive Disorders (HAND)

Brown, L. A. M., Jin, J., Ferrell, D., Sadic, E., Obregon, D. F., Smith, A. J., Tan, J., & Giunta, B. N. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095500 · Cited by 59

Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer’s disease

Ewers, M., Cheng, X., Zhong, Z., Nural, H. F., Walsh, C., Meindl, T., Teipel, S. J., Buerger, K., He, P., Shen, Y., et al. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-091153 · Cited by 58

AD synapses contain abundant Aβ monomer and multiple soluble oligomers, including a 56-kDa assembly

Sokolow, S., Henkins, K. M., Bilousova, T. V., Miller, C. A., Vinters, H. V., Poon, W. W., Cole, G. M., & Gylys, K. H. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.05.011 · Cited by 61

Alzheimers Disease: Pathological Mechanisms and Recent Insights

Niedowicz, D. M., Nelson, P. T., & Murphy, M. P. (2011) · Current Neuropharmacology · doi:10.2174/157015911798376181 · Cited by 62

Pharmacotherapeutic targets in Alzheimer's disease

Biran, Y., Masters, C. L., Barnham, K. J., Bush, A. I., & Adlard, P. A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00595.x · Cited by 59

Calcium in the initiation, progression and as an effector of Alzheimer’s disease pathology

Green, K. N. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00861.x · Cited by 56

Detection of Aβ oligomers based on magnetic-field-assisted separation of aptamer-functionalized Fe 3 O 4 magnetic nanoparticles and BaYF 5 :Yb,Er nanoparticles as upconversion fluorescence labels

Jiang, L., Chen, B.-C., Chen, B., Li, X.-J., Liao, H., Huang, H., Guo, Z., Zhang, W., & Wu, L. H. (2017) · Talanta · doi:10.1016/j.talanta.2017.04.021 · Cited by 57

Blocking the apolipoprotein E/Amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology

Liu, S., Breitbart, A., Sun, Y., Mehta, P. D., Boutajangout, A., Scholtzova, H., & Wisniewski, T. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12484 · Cited by 60

Synapse-Binding Subpopulations of Aβ Oligomers Sensitive to Peptide Assembly Blockers and scFv Antibodies

Velasco, P. T., Heffern, M. C., Sebollela, A. S., Popova, I. A., Lacor, P. N., Lee, K. B., Sun, X., Tiano, B. N., Viola, K. L., Eckermann, A. L., et al. (2012) · ACS Chemical Neuroscience · doi:10.1021/cn300122k · Cited by 57

Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases—From pathophysiology to clinical practice

Blennow, K., Biscetti, L., Eusebi, P., & Parnetti, L. (2016) · Movement Disorders · doi:10.1002/mds.26656 · Cited by 61

Amyloid-β and Cognition in Aging and Alzheimer's Disease: Molecular and Neurophysiological Mechanisms

Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129003 · Cited by 57

N-truncated Abeta starting with position four: Early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody

Antonios, G., Saiepour, N., Bouter, Y., Richard, B. C., Paetau, A., Verkkoniemi-Ahola, A., Lannfelt, L., Ingelsson, M., Kovacs, G. G., Pillot, T., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-56 · Cited by 53

Protection against Aβ-mediated rapid disruption of synaptic plasticity and memory by memantine

Klyubin, I., Wang, Q., Reed, M. N., Irving, E. A., Upton, N., Hofmeister, J., Cleary, J. P., Anwyl, R., & Rowan, M. J. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.005 · Cited by 69

β-Amyloid oligomers in aging and Alzheimer’s disease

Zahs, K. R., & Ashe, K. H. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00028 · Cited by 55

Targeting the Nogo Receptor Complex in Diseases of the Central Nervous System

McDonald, C., Bandtlow, C. E., & Reindl, M. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711794088326 · Cited by 53

Synaptic plasticity modulation by circulating peptides and metaplasticity: Involvement in Alzheimer’s disease

Peineau, S., Rabiant, K., Pierrefiche, O., & Potier, B. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.018 · Cited by 56

Extracellular vesicles: where the amyloid precursor protein carboxyl‐terminal fragments accumulate and amyloid‐β oligomerizes

Pérez‐González, R., Kim, Y., Miller, C., Pacheco‐Quinto, J., Eckman, E. A., & Levy, E. (2020) · The FASEB Journal · doi:10.1096/fj.202000823r · Cited by 57

Neuroinflammation

Mukhara, D., Oh, U., & Neigh, G. N. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00017-5 · Cited by 60

Association of the RAGE G82S polymorphism with Alzheimer’s disease

Daborg, J., von Otter, M., Sjölander, A., Nilsson, S., Minthon, L., Gustafson, D., Skoog, I. G., Blennow, K., & Zetterberg, H. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0437-0 · Cited by 52

Activated Bone Marrow-Derived Macrophages Eradicate Alzheimer's-Related Aβ42 Oligomers and Protect Synapses

Li, S., Hayden, E. Y., Garcia, V. J., Fuchs, D.-T. S., Sheyn, J., Daley, D. A., Rentsendorj, A., Torbati, T., Black, K. L., Rutishauser, U., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00049 · Cited by 48

Vaccination as a Therapeutic Approach to Alzheimer's Disease

Wısnıewskı, T., & Boutajangout, A. (2010) · Mount Sinai Journal of Medicine A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20156 · Cited by 53

Alzheimer disease and neuroplasticity

Koch, G., & Spampinato, D. A. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00027-8 · Cited by 50

Cerebrospinal fluid and blood biomarkers in Alzheimer’s disease

Humpel, C. (2011) · World Journal of Psychiatry · doi:10.5498/wjp.v1.i1.8 · Cited by 54

Brain Inflammation Connects Cognitive and Non-Cognitive Symptoms in Alzheimer’s Disease

Sellés, M. C., Oliveira, M. M., & Ferreira, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179925 · Cited by 51

Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta

Rofo, F., Buijs, J., Falk, R., Honek, K., Lannfelt, L., Lilja, A. M., Metzendorf, N. G., Gustavsson, T., Sehlin, D., Söderberg, L., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00258-x · Cited by 50

Reversible Pathologic and Cognitive Phenotypes in an Inducible Model of Alzheimer-Amyloidosis

Melnikova, T., Fromholt, S., Kim, H.-S., Lee, D., Xu, G. M., Price, A. R., Moore, B. D., Golde, T. E., Felsenstein, K. M., Savonenko, A. V., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.4251-12.2013 · Cited by 51

Controlled in situ preparation of Aβ(1–42) oligomers from the isopeptide “iso-Aβ(1–42)”, physicochemical and biological characterization

Bozsó, Z., Penke, B., Simon, D., Laczkó, I., Juhász, G., Szegedi, V., Kasza, Á., Soós, K., Hetényi, A., Wéber, E., et al. (2009) · Peptides · doi:10.1016/j.peptides.2009.12.001 · Cited by 48

Bioactive human Alzheimer brain soluble Aβ: pathophysiology and therapeutic opportunities

Li, S., & Stern, A. M. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01589-5 · Cited by 47

Oligomerization Partially Explains the Lowering of Aβ42 in Alzheimer’s Disease Cerebrospinal Fluid

Englund, H., Gunnarsson, M. D., Brundin, R., Hedlund, M., Kilander, L., Lannfelt, L., & Pettersson, F. E. (2009) · Neurodegenerative Diseases · doi:10.1159/000225376 · Cited by 49

Development and validation of a yeast high-throughput screen for inhibitors of Aβ42 oligomerization

Park, S.-K., Pegan, S. D., Mesecar, A. D., Jungbauer, L. M., LaDu, M. J., & Liebman, S. W. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007963 · Cited by 50

Piperazine sulfonamide BACE1 inhibitors: Design, synthesis, and in vivo characterization

Cumming, J. N., Babu, S., Huang, Y., Carroll, C. D., Chen, X., Favreau, L. V., Greenlee, W. J., Guo, T., Kennedy, M. E., Kuvelkar, R., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.050 · Cited by 47

On the Use of TMS to Investigate the Pathophysiology of Neurodegenerative Diseases

Rawji, V., Latorre, A., Sharma, N., Rothwell, J. C., & Rocchi, L. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.584664 · Cited by 47

Synthesis and evaluation of multi-target-directed ligands with BACE-1 inhibitory and Nrf2 agonist activities as potential agents against Alzheimer’s disease

Qu, L., Ji, L., Wang, C., Luo, H., Li, S., Peng, W., Yin, F., Lu, D., Liu, X., Kong, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113441 · Cited by 47

Memantine prevents memory consolidation failure induced by soluble beta amyloid in rats

Tucci, P., Mhillaj, E., Morgese, M. G., Colaianna, M., Zotti, M., Schiavone, S., Cicerale, M., Trezza, V., Campolongo, P., Cuomo, V., et al. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00332 · Cited by 49

TV 3326 for Alzheimer’s dementia: a novel multimodal ChE and MAO inhibitors to mitigate Alzheimer’s-like neuropathology

Uddin, M. S., Kabir, M. T., Rahman, M. M., Mathew, B., Shah, M. A., & Ashraf, G. M. (2020) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13244 · Cited by 44

Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease: The Present and the Future

Ghidoni, R., Benussi, L., Paterlini, A., Albertini, V., Binetti, G. G., & Emanuele, E. (2011) · Neurodegenerative Diseases · doi:10.1159/000327756 · Cited by 44

β-amyloid and Oxidative Stress: Perspectives in Drug Development

Caruso, G., Spampinato, S. F., Cardaci, V., Caraci, F., Sortino, M. A., & Merlo, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191209115431 · Cited by 45

Oral Treatment with a γ-Secretase Inhibitor Improves Long-Term Potentiation in a Mouse Model of Alzheimer's Disease

Townsend, M., Qu, Y., Gray, A. J., Wu, Z., Seto, T., Hutton, M., Shearman, M. S., & Middleton, R. E. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.163691 · Cited by 42

Direct Evidence of the Presence of Cross-Linked Aβ Dimers in the Brains of Alzheimer’s Disease Patients

de la Torre, A. V., Gay, M., Vilaprinyó-Pascual, S., Mazzucato, R., Serra-Batiste, M., Vilaseca, M., & Carulla, N. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.7b04936 · Cited by 42

New diagnostic method for Alzheimer’s disease based on the toxic conformation theory of amyloid β

Irie, K. (2019) · Bioscience Biotechnology and Biochemistry · doi:10.1080/09168451.2019.1667222 · Cited by 41

Vaccination with Aβ-Displaying Virus-Like Particles Reduces Soluble and Insoluble Cerebral Aβ and Lowers Plaque Burden in APP Transgenic Mice

Bach, P., Tschäpe, J., Kopietz, F., Braun, G., Baade, J. K., Wiederhold, K., Staufenbiel, M., Prinz, M., Deller, T., Kalinke, U., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0803366 · Cited by 44

A Universal Method for Detection of Amyloidogenic Misfolded Proteins

Yam, A. Y.-W., Wang, X., Gao, C. M., Connolly, M. D., Zuckermann, R. N., Bleu, T., Hall, J., Fedynyshyn, J. P., Allauzen, S., Peretz, D., et al. (2011) · Biochemistry · doi:10.1021/bi200215j · Cited by 39

Aβ1–42 Detection in CSF of Alzheimer's disease is influenced by temperature: Indication of reversible Aβ1–42 aggregation?

Sancesario, G. M., Esposito, Z., Nuccetelli, M., Bernardini, S., Sorge, R. P., Martorana, A., Federici, G., Bernardi, G., & Sancesario, G. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.028 · Cited by 40

Naphthoquinone-tyrptophan reduces neurotoxic Aβ*56 levels and improves cognition in Alzheimer's disease animal model

Scherzer‐Attali, R., Farfara, D., Cooper, I., Levin, A., Benromano, T., Trudler, D., Vientrov, M., Shaltiel‐Karyo, R., Shalev, D. E., Segev‐Amzaleg, N., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.005 · Cited by 40

Immunotherapeutic approaches for Alzheimer’s disease in transgenic mouse models

Wısnıewskı, T., & Boutajangout, A. (2009) · Brain Structure and Function · doi:10.1007/s00429-009-0236-2 · Cited by 39

Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease

Picón-Pagès, P., Bonet, J., Garcı́a-Garcı́a, J., Garcia-Buendia, J., Gutiérrez, D. A., Valle, J., Gómez-Casuso, C. E. S., Sidelkivska, V., Alvarez, A. R., Perálvarez‐Marín, A., et al. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.06.017 · Cited by 39

Biological basis for amyloidogenesis in Alzheimer’S disease

Андреева, Т. В., Lukiw, W. J., & Rogaev, E. I. (2017) · Biochemistry (Moscow) · doi:10.1134/s0006297917020043 · Cited by 38

Cationization increases brain distribution of an amyloid-beta protofibril selective F(ab’)2 fragment

Syvänen, S., Edén, D., & Sehlin, D. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.09.065 · Cited by 36

Protein misfolding cyclic amplification (PMCA): Current status and future directions

Saá, P., & Červen̆áková, L. (2014) · Virus Research · doi:10.1016/j.virusres.2014.11.007 · Cited by 37

Tissue Transglutaminase-mediated Glutamine Deamidation of β-Amyloid Peptide Increases Peptide Solubility, Whereas Enzymatic Cross-linking and Peptide Fragmentation May Serve as Molecular Triggers for Rapid Peptide Aggregation

Schmid, A. W., Condemi, E., Tuchscherer, G., Chiappe, D., Mutter, M., Vogel, H., Moniatte, M., & Tsybin, Y. O. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.176149 · Cited by 37

The Load of Amyloid-β Oligomers is Decreased in the Cerebrospinal Fluid of Alzheimer's Disease Patients

Sancesario, G. M., Cencioni, M. T., Esposito, Z., Borsellino, G., Nuccetelli, M., Martorana, A., Battistini, L., Roberto, S., Spalletta, G., Ferrazzoli, D., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120211 · Cited by 34

FLZ Alleviates the Memory Deficits in Transgenic Mouse Model of Alzheimer’s Disease via Decreasing Beta-Amyloid Production and Tau Hyperphosphorylation

Bao, X.-Q., Li, N., Wang, T., Kong, X., Tai, W., Sun, H., & Zhang, D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078033 · Cited by 34

Can magnesium reduce central neurodegeneration in Alzheimer's disease? Basic evidences and research needs

Toffa, D. H., Magnerou, M. A., Kassab, A., Djibo, F. H., & Sow, A. D. (2019) · Neurochemistry International · doi:10.1016/j.neuint.2019.03.014 · Cited by 33

Acute Pannexin 1 Blockade Mitigates Early Synaptic Plasticity Defects in a Mouse Model of Alzheimer’s Disease

Flores‐Muñoz, C., Gómez, B., Mery, E., Mujica, P., Gajardo, I., Córdova, C., López-Espíndola, D., Duran-Aniotz, C. A., Hetz, C. A., Muñoz, P., et al. (2020) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2020.00046 · Cited by 34

Structural Diversity of Alzheimer's Disease Amyloid-β Dimers and Their Role in Oligomerization and Fibril Formation

Tsigelny, I. F., Sharikov, Y., Kouznetsova, V. L., Greenberg, J. P., Wrasidlo, W., Gonzalez, T., Desplats, P., Michael, S. E., Trejo, M., Overk, C., et al. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-131589 · Cited by 33

Ginkgolic Acid Protects against Aβ-Induced Synaptic Dysfunction in the Hippocampus

Mango, D., Weisz, F., & Nisticò, R. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00401 · Cited by 33

Abeta(1-42) Enhances Neuronal Excitability in the CA1 via NR2B Subunit-Containing NMDA Receptors

Varga, E., Juhász, G., Bozsó, Z., Penke, B., Fülöp, L., & Szegedi, V. (2014) · Neural Plasticity · doi:10.1155/2014/584314 · Cited by 35

Inhibiting the Ca2+ Influx Induced by Human CSF

Drews, A., De, S., Flagmeier, P., Wirthensohn, D. C., Chen, W., Whiten, D. R., Rodrigues, M., Vincke, C., Muyldermans, S., Paterson, R. W., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.057 · Cited by 33

Metal attenuating therapies in neurodegenerative disease

Mot, A. I., Wedd, A. G., Sinclair, L., Brown, D. R., Collins, S. J., & Brazier, M. W. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.170 · Cited by 32

Synthetic Models of Quasi-Stable Amyloid β40 Oligomers with Significant Neurotoxicity

Irie, Y., Murakami, K., Hanaki, M., Hanaki, Y., Suzuki, T., Monobe, Y., Takai, T., Akagi, K., Kawase, T., Hirose, K., et al. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00390 · Cited by 31

PPAR-α agonist regulates amyloid-β generation via inhibiting BACE-1 activity in human neuroblastoma SH-SY5Y cells transfected with APPswe gene

Zhang, H., Gao, Y., Qiao, P., Zhao, F., & Yan, Y. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2480-5 · Cited by 32

Metallo-complex activation of neuroprotective signalling pathways as a therapeutic treatment for Alzheimer’s disease

Bica, L., Crouch, P. J., Cappai, R., & White, A. R. (2008) · Molecular BioSystems · doi:10.1039/b816577g · Cited by 33

A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain‐derived synaptic plasticity‐disrupting Aβ

O’Nuallain, B., Klyubin, I. V., Donald, J. M. M., Foster, J. S., Welzel, A. T., Barry, A. E., Dykoski, R. K., Cleary, J. P., Gebbink, M. F. B. G., Rowan, M. J., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07389.x · Cited by 33

Quantifying Prefibrillar Amyloids in vitro by Using a “Thioflavin‐Like” Spectroscopic Method

Reinke, A. A., Abulwerdi, G. A., & Gestwicki, J. E. (2010) · ChemBioChem · doi:10.1002/cbic.201000358 · Cited by 30

Monomeric amyloid-β reduced amyloid-β oligomer-induced synapse damage in neuronal cultures

Bate, C., & Williams, A. (2017) · Neurobiology of Disease · doi:10.1016/j.nbd.2017.12.007 · Cited by 30

Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins

Lambert, M., Velasco, P., Viola, K., & Klein, W. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709787601876 · Cited by 29

Peripheral Interventions Enhancing Brain Glutamate Homeostasis Relieve Amyloid β- and TNFα- Mediated Synaptic Plasticity Disruption in the Rat Hippocampus

Zhang, D., Mably, A. J., Walsh, D. M., & Rowan, M. J. (2016) · Cerebral Cortex · doi:10.1093/cercor/bhw193 · Cited by 29

Extrinsic Amyloid-Binding Dyes for Detection of Individual Protein Aggregates in Solution

Taylor, C. G., Meisl, G., Horrocks, M. H., Zetterberg, H., Knowles, T. P. J., & Klenerman, D. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b02226 · Cited by 29

Anti-amyloidogenic Activity of IgGs Contained in Normal Plasma

O’Nuallain, B., Williams, A. D., McWilliams‐Koeppen, H. P., Acero, L. F., Weber, A., Ehrlich, H. J., Schwarz, H. P., & Solomon, A. (2010) · Journal of Clinical Immunology · doi:10.1007/s10875-010-9413-6 · Cited by 27

Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease

Teipel, S. J., Sabri, O., Grothe, M. J., Barthel, H., Prvulovic, D., Büerger, K., Bokde, A. L. W., Ewers, M., Hoffmann, W. U., & Hampel, H. J. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-129030 · Cited by 27

Aggregation, impaired degradation and immunization targeting of amyloid-beta dimers in Alzheimer’s disease: a stochastic modelling approach

Proctor, C. J., Pienaar, I. S., Elson, J. L., & Kirkwood, T. B. L. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-32 · Cited by 27

Amyloid-β oligomers increase the binding and internalization of tau oligomers in human synapses

Kadamangudi, S., Marcatti, M., Zhang, W.-R., Fracassi, A., Kayed, R., Limon, A., & Taglialatela, G. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02839-2 · Cited by 25

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

Siemers, E., Hitchcock, J., Sundell, K. L., Dean, R. A., Jerecic, J., Cline, E. N., Iverson, K., Moore, J. A., Edgar, C. J., Manber, R., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.93 · Cited by 26

Preventive immunization of aged and juvenile non-human primates to beta-amyloid

Kofler, J., Lopresti, B. J., Janssen, C., Trichel, A. M., Masliah, E., Finn, O. J., Salter, R. D., MURDOCH, G. H., Mathis, C. A., & Wiley, C. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-84 · Cited by 26

The Aggregation Paths and Products of Aβ42 Dimers Are Distinct from Those of the Aβ42 Monomer

O’Malley, T. T., Wittbold, W. M., Linse, S. S., & Walsh, D. M. (2016) · Biochemistry · doi:10.1021/acs.biochem.6b00453 · Cited by 24

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.

Anwyl, R., Klyubin, I. V., & ROWAN, M. (2008) · Arrow@dit (Dublin Institute of Technology)

Amyloid β protein immunotherapy neutralizes Aβ oligomers that disrupt synaptic plasticity in vivo

Klyubin, I., Walsh, D. M., Lemere, C. A., Cullen, W. K., Shankar, G. M., Betts, V., Spooner, E. T., Jiang, L., Anwyl, R., Selkoe, D. J., et al. (2005) · Nature Medicine · doi:10.1038/nm1234 · Cited by 489

Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo

Walsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291

Synaptic plasticity disruption by amyloid β protein: modulation by potential Alzheimer's disease modifying therapies

Rowan, M. J., Klyubin, I. V., Wang, Q., & Anwyl, R. (2005) · Biochemical Society Transactions · doi:10.1042/bst0330563 · Cited by 83

S1‐02–03: Synthetic Abeta dimers and Abeta dimers from CSF and Alzheimer brain disrupt synaptic plasticity and memory

Walsh, D. M. (2008) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2008.05.192